AVORO CAPITAL ADVISORS LLC 13D and 13G filings for Spyre Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-14 09:35 am Sale |
2024-09-30 | 13G | Spyre Therapeutics, Inc. SYRE |
AVORO CAPITAL ADVISORS LLC | 885,059 1.700% |
-954,079 (-51.88%) |
Filing |
| 2024-04-23 6:22 pm Sale |
2023-12-31 | 13G | Spyre Therapeutics, Inc. SYRE |
AVORO CAPITAL ADVISORS LLC | 1,839,138 5.100% |
-286,459 (-13.48%) |
Filing |
| 2024-02-14 09:08 am Purchase |
2023-12-31 | 13G | Spyre Therapeutics, Inc. SYRE |
AVORO CAPITAL ADVISORS LLC | 2,125,597 5.900% |
2,125,597 (New Position) |
Filing |